Studies have indicated that PSMA PET/CT demonstrates high sensitivity and specificity in identifying local and distant metastases (49, 53), particularly in high-risk prostate cancer patients, where its diagnostic accuracy surpasses that of traditional imaging methods (CT and MRI) (54). This evidence concerns the gene FOLH1 and prostate carcinoma.